Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pfizer announced last month that it was discontinuing development of its experimental weight-loss pill, danuglipron, after a trial participant experienced potential drug-induced liver injury.

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...